Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 7/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 7/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15312682 | 0.88 | DCTPP1 (0.42) | CSF1RDCTPP1TXNRD1S1PR4MAPT | |
| SCHEMBL15312690 | 0.87 | CSF1R (0.47) | CSF1RDCTPP1TXNRD1S1PR4MAPT | |
| SCHEMBL2048309 | 0.85 | CSF1R (0.45) | CSF1RDCTPP1 | |
| SCHEMBL2049191 | 0.84 | CSF1R (0.39) | CSF1RDCTPP1TXNRD1S1PR4MAPT | |
| SCHEMBL1172483 | 0.80 | DCTPP1 (0.55) | DCTPP1MAPTRAB9A | |
| SCHEMBL2052880 | 0.80 | CSF1R (0.40) | CSF1RDCTPP1RAB9A | |
| SCHEMBL2052873 | 0.78 | DCTPP1 (0.39) | CSF1RDCTPP1 | |
| SCHEMBL2047820 | 0.78 | CSF1R (0.45) | CSF1RDCTPP1MAPTGFER | |
| SCHEMBL9941860 | 0.77 | CSF1R (0.43) | CSF1RDCTPP1MAPTMAPK1 | |
| SCHEMBL2052346 | 0.77 | CSF1R (0.41) | CSF1RDCTPP1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102822170-B | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2014-12-10 | — | — | CN | disclosed |
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2516433-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-05-21 | — | — | EP | disclosed |
| CN-102822170-A | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2012-12-12 | — | — | CN | disclosed |
| EP-2516433-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | Array Biopharma, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | CSF1R 17/4885DCTPP1 3473/4885TXNRD1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.